A two-drug combination extended OS compared with standard first-line osimertinib for certain patients with advanced lung ...
Posdinemab is an investigational monoclonal antibody that targets the mid-domain of Alzheimer's disease-specific ...
Bernstein lowered the firm’s price target on Johnson & Johnson to $160 from $177 and keeps a Market Perform rating on the shares as part of a ...
First-line Rybrevant plus Lazcluze improved survival versus the current standard of care in patients with mutated advanced or ...
The already crowded field of biomarker-targeted drugs is poised to only get busier with new biomarkers, ADCs, and cancer vaccines.
In this edition of InnovationRx, medical debts will be erased from credit histories, this farm is doubling down on raw milk ...
Shares of Sana Biotechnology Inc. (NASDAQ: SANA) were trading at $4.97, up $3.32, or 201%, on first results from an investigator-sponsored, first-in-human study transplanting UP-421, an allogeneic ...
Johnson & Johnson released results from a phase 3 study, showing that the combination of Rybrevant and Lazcluze significantly improved overall survival in patients with advanced non-small cell lung ...
1d
Ram Selvaraju, an analyst from H.C. Wainwright, reiterated the Buy rating on Genmab (GMAB – Research Report). The associated price target ...
Johnson & Johnson (J&J) has reported positive topline outcomes from the Phase III MARIPOSA trial of Rybrevant ...
Johnson & Johnson's Rybrevant and Lazcluze combination shows significant overall survival benefits over Tagrisso in the ...
Johnson & Johnson's recently approved combination of Rybrevant and Lazcluze has improved overall survival compared to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback